Federal health advisers on Tuesday narrowly backed an experimental vaccine from Pfizer that could soon become the first shot to protect older adults against...
WASHINGTON — Federal health advisers on Tuesday narrowly backed an experimental vaccine from Pfizer that could soon become the first shot to protect older adults against the respiratory illness known as RSV.
The positive vote came despite concerns about rare potential reactions and questions about how the vaccine fared in people who face the greatest risks from RSV. Pfizer’s shot was more than 85% effective at preventing severe disease in a company study, but panelists noted there were few people with underlying health problems.
The FDA panel is also reviewing another proposed RSV vaccine from GlaxoSmithKline GSK . The FDA panel is scheduled to review and vote on GSK’s shot, which is also designed to prevent respiratory disease in older adults, on Wednesday.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
FDA advisors recommend Pfizer RSV vaccine for older adults, despite possible Guillain-Barre risks
Read more »
FDA warns of Guillain-Barre syndrome as possible risk of Pfizer’s RSV vaccineGuillain-Barre syndrome, or inflammatory neuropathy, is a disorder in which the body’s immune system mistakenly attacks the nerves.
Read more »
Pfizer, GSK face FDA panel review in race for RSV vaccinesThe frontrunners in a crowded race to develop the first respiratory syncytial virus (RSV) vaccine - Pfizer Inc and GSK - will face scrutiny from a panel of experts to the U.S. Food and Drug Administration this week.
Read more »
Paving the way for the world's first RSV vaccine, FDA advisers recommend shot from PfizerBREAKING: FDA advisers recommend that the agency approve the country’s first RSV vaccine for older people, a shot from Pfizer for adults ages 60 and up.
Read more »
Doctors who touted ivermectin as covid fix now pushing it for flu, RSVFirst, the group of doctors championed ivermectin as a covid panacea. It failed to live up to the hype. Now, they’re promoting the anti-parasitic to prevent and treat the flu and RSV.
Read more »
A single injection could protect babies against RSV over winterRSV infections kill around 100,000 children each year, but now an antibody injection has proven safe and effective at reducing the risk from the disease.
Read more »